Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size, Growth Report By 2032

Published Date : 27 Feb 2024

The global enzyme-linked immunosorbent assay (ELISA) testing market size was exhibited at USD 2 billion in 2022 and is anticipated to touch around USD 3.43 billion by 2032, expanding at a CAGR of 5.60% from 2023 to 2032.

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size and Growth Rate From 2023 to 2032

Market Overview

The enzyme-linked immunosorbent assay (ELISA) testing market is a specialized industry that deals with the production, distribution, and application of ELISA testing kits and services. ELISA is a widely used diagnostic technique that detects the presence of antibodies, antigens, proteins, or hormones in a sample through the interaction with enzymes and specific antibodies. The enzyme-linked immunosorbent assay (ELISA) testing market involves a range of stakeholders, including manufacturers of ELISA kits, healthcare providers who offer ELISA testing services, research institutions that use ELISA in biomedical research, and regulatory bodies that monitor the quality and standards of ELISA products.

The enzyme-linked immunosorbent assay (ELISA) testing market is experiencing rapid growth due to several key factors. Firstly, the rising prevalence of chronic diseases, such as cancer, cardiovascular disorders, and infectious diseases, is driving demand for accurate and reliable diagnostic methods like ELISA testing. Secondly, continuous advancements in ELISA technology, such as improved sensitivity, automation, and multiplexing capabilities, are enhancing its efficiency and expanding its application spectrum, attracting both healthcare providers and research institutions.

Additionally, the growing focus on early disease detection and preventive healthcare initiatives further boosts the adoption of ELISA testing, as it offers high sensitivity and specificity in detecting biomarkers associated with various diseases. Furthermore, the untapped potential of emerging markets, particularly in Asia-Pacific and Latin America, presents promising avenues for market expansion, owing to rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about diagnostic technologies. Overall, these factors contribute to the sustained growth of the enzyme-linked immunosorbent assay (ELISA) testing market globally.

Regional Snapshot

North America is the dominating player in the enzyme-linked immunosorbent assay (ELISA) testing market, dominating in terms of market share and innovation. The region's healthcare infrastructure is well-established, and its research and development activities are robust, which, coupled with the high prevalence of chronic diseases, has resulted in an increased demand for accurate diagnostic measures like ELISA testing. The presence of market leaders, academic research institutions, and pharmaceutical companies further stimulates market growth through collaborations, product development initiatives, and clinical trials.

The region's stringent regulatory frameworks and quality standards ensure the reliability and accuracy of ELISA testing kits and services, instilling confidence among healthcare providers and patients alike. Furthermore, North America's focus on early disease detection, preventive healthcare measures, and personalized medicine fosters the adoption of advanced diagnostic technologies like ELISA testing. 

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Report Scope:

Report Coverage Details
Market Revenue in 2023 USD 2.10 Billion
Projected Forecast Revenue by 2032 USD 3.43 Billion
Growth Rate from 2023 to 2032 CAGR of 5.60%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Dynamics


Rising prevalence of chronic diseases

There has been a notable increase in the prevalence of chronic illnesses such as cancer, cardiovascular diseases, and diabetes. This trend has resulted in a surge in demand for advanced diagnostic techniques, particularly ELISA testing. ELISA has emerged as the preferred diagnostic tool among healthcare professionals due to its high accuracy in detecting and measuring specific biomarkers associated with these chronic diseases. ELISA testing boasts excellent sensitivity and specificity, making it a reliable method for diagnosing and monitoring the progression of these diseases.

Growing focus on early disease detection

There has been a significant shift towards prevention and early detection of diseases in recent years. This has resulted in an increasing emphasis on the importance of diagnostic tests that can identify the presence of diseases in their early stages. One such testing method that has gained popularity in early screening programs is ELISA testing. ELISA tests are highly sensitive and specific in detecting diseases, making them the preferred choice in early screening programs. These tests can detect even small amounts of specific proteins or antibodies in bodily fluids like blood, even before the appearance of disease symptoms.


High cost of ELISA test kits

The ELISA is a well-known diagnostic test used to identify antibodies or antigens in biological samples. While it is highly effective, the high cost of ELISA test kits remains a significant challenge, especially in developing regions with limited healthcare budgets. The cost of ELISA testing is a concern, as it can be a significant burden for resource-constrained settings. The high cost of ELISA testing hampers its widespread adoption, limiting the ability of healthcare providers to diagnose and treat specific diseases. This emphasizes the need for more cost-effective and accessible diagnostic tests that can be used in resource-constrained settings.

Competition from alternative diagnostic technologies

The enzyme-linked immunosorbent assay (ELISA) testing market, which is a popular diagnostic tool that helps in detecting and measuring antibodies or antigens in biological samples, is facing stiff competition from alternative diagnostic technologies such as Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Point-of-Care Testing (POCT). These technologies provide rapid results with high sensitivity and are posing a significant threat to the growth of the ELISA testing market. PCR is widely used for detecting DNA, while NGS is a more advanced technology that enables the sequencing of multiple DNA strands at once. POCT is a portable, user-friendly test that facilitates quick diagnosis at the point of care.


Expanding applications in drug development and research

The enzyme-linked immunosorbent assay (ELISA) testing market has emerged as a valuable tool for drug development, clinical trials, and biomedical research. It offers ample opportunities for market players operating in these industries. ELISA assays are extensively used in screening and identifying potential drug candidates, evaluating the efficacy of treatments, and monitoring disease progression. They are highly sensitive and specific, making them the preferred choice for identifying biomarkers and detecting analytes in biological samples.

Emerging markets in Asia-Pacific and Latin America

The enzyme-linked immunosorbent assay (ELISA) testing market is currently witnessing substantial growth opportunities in the emerging markets of Asia-Pacific and Latin America. These regions have significant untapped potential due to the rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about diagnostic technologies. The enzyme-linked immunosorbent assay (ELISA) testing players are utilizing these opportunities and expanding their market presence in these regions. The increasing prevalence of chronic diseases, such as cancer and diabetes, in these regions is further boosting the demand for ELISA Testing, which helps in early diagnosis and effective treatment.

  • In June 2023, INVEX Health announced the upcoming launch of India's first oral HIV self-test. This innovative self-test is expected to provide a convenient and reliable way for individuals to test themselves for HIV without the need for a medical professional. The test is designed to be easy to use and accurate, using advanced technology to detect the presence of HIV antibodies in a person's saliva.

Recent Developments

  • In December 2023, LANSING launched an enhanced ELISA product called Veratox VIP assay that is capable of detecting walnut allergens. 0.15 ppm of walnut protein can be detected in the assay. It is considered one of the lowest concentrations for the ELISA test. The assay can be conducted on different products and processing environments. Veratox VIP is essential for enhancing food quality and safety.
  • In October 2023, two new rapid ELISA systems were launched by Lonza. The two new systems are the PyroCell MAT Human Serum Rapid System and the Pyrocell MAT Rapid System. The system is more efficient and reduces hands-on time and time-to-results. It takes only two hours for the overall work and results instead of 2 days.

Major Key Players

  • Thermo Fisher Scientific, Inc.
  • American Laboratory Products Company (ALPCO)
  • Bio-Rad Laboratories, Inc.
  • BD
  • BioMérieux SA
  • Ortho Clinical Diagnostics
  • R&D Systems, Inc.
  • ZEUS Scientific, Inc.

Market Segmentation

By Test Type

  • Sandwich ELISA
  • Indirect ELISA
  • Multiple and Portable ELISA
  • Competitive ELISA
  • Others

By Application

  • Immunology
  • Inflammation
  • Infectious diseases
  • Cancer
  • Protein quantification
  • Other Applications

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1260

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308